In April, Sandoz leveraged a private-label agreement in the US to accelerate patient switching to its biosimilar; Hyrimoz® (adalimumab ... new standalone financing structure following the ...

Patients with radiographic axial spondyloarthritis who receive ixekizumab biweekly demonstrate lower sacroiliac joint erosion and increased the backfill of new tissue through 52 weeks, according to ...

FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2.7 billion, up by 9% in constant currencies (+7% in USD) Strong sales performances in ...

REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar ...

Four qualities that elevate this paper from good to great in style are: its structure, captivity, soulfulness, and precision. Structured Outline, Paragraphs, and Sentences Structurally ...

Alvotech SA reported a significant revenue increase in Q4 2024, with total revenues reaching $492 million, a 400% growth compared to the previous year. Despite this, the company reported an ...

As with other drugs, Humira (adalimumab) can cause side effects, such as headache and injection site reactions. If you are not able to tolerate side effects of Humira, talk with your doctor or ...

Alvotech, a biotech firm focused on biosimilar medicine development, announced the acquisition of Xbrane Biopharma’s R&D operations and a biosimilar candidate named XB003, aimed at extending its ...